U.S. Nurses Believe They Considerably Influence Patient Health Decisions and Behavior

Manhattan ResearchAccording to pharmaceutical and healthcare market research company Manhattan Research, U.S. nurses believe they considerably influence patients' health decisions and behavior. The Taking the Pulse® Nurses v10.0 study found that the majority of online nurses report that they influence how their patients follow through with their treatment regimens. The study also found that most online nurses encourage patients to take advantage of health and condition websites and are significantly more likely than physicians to recommend these resources to their patients. The research is based on interviews with over 1,000 U.S. nurses and physician assistants (PAs) and focuses on the media and device preferences, professional resource mix, and digital behaviors and attitudes of these segments.

"Marketers shouldn't underestimate the influence nurses have on how patients think about medication and follow their treatment plan. This new nursing study, as well as past consumer studies, unequivocally show that nurses play a pivotal role in this regard," said Monique Levy, Senior Director of Research at Manhattan Research. "We've seen several brands and marketers already jump on this opportunity - especially given the flux in physician-directed promotion these days."

About Taking the Pulse® Nurses
The Taking the Pulse® Nurses study was conducted in Q2 2010 among 1,023 U.S. practicing nurses and physician assistants (PAs) via online survey methodology. Key topics include technology and Internet use for professional purposes; resources like medical references, journals, and conferences; email use and opportunity; patient interaction and educational sources; handheld devices and mobile activities; practice technology such as electronic prescribing and EMR; continuing education; and digital interaction with pharma companies, including product and corporate websites and HCP service portals.

Healthcare and pharmaceutical marketers and other industry stakeholders use Taking the Pulse® Nurses to examine technology, media, channel, and promotional mix strategies, as well as to benchmark their performance against industry competitors. In addition to analyzing overall market trends, clients will be able to segment the study to derive statistically relevant insights across over twenty specialist groups.

For additional product and subscription information, please visit:
http://www.manhattanresearch.com/ttpnurses

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm and conducts annual research studies covering eHealth trends among physicians and consumers, including Taking the Pulse®, Taking the Pulse® Nurses, Taking the Pulse® Europe, Taking the Pulse® Asia, Cybercitizen Health®, Cybercitizen Health® Europe, ePharma Consumer®, and ePharma Physician®. Broad consumer and physician research is complemented by targeted analysis for over 100 consumer therapeutic segments and physician specialist segments. For more information, please visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.decisionresourcesinc.com.

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...